Dynamics of changes of the BNP concentration in patients with stable angina pectoris qualified for PTCA. Dependence on the selected morphological and haemodynamic parameters

Archives of Medical Science

Volumn 2, Issue 1, 2006, Pages 15-19

  Irzmański, Robert ^a   Piechota, Mariusz ^a   Barylski, Marcin ^a   Banach, Maciej ^a   Gławȩda, Beata ^a   Kowalski, Jan ^a   Cierniewski, Czesław ^a   Kośmider, Maciej ^a   Pawlicki, Lucjan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

BNP; PTCA; Stable angina pectoris

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ANGIOCARDIOGRAPHY; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CORONARY BLOOD VESSEL; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; EMERGENCY TREATMENT; EVALUATION; FEMALE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE; HEMODYNAMIC MONITORING; HUMAN; MALE; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 33645763022     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94.
2. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
3. Kinnunen P, Vuolteenano O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132: 1961-70.
4. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens 1992; 10: 1111-4.
5. Bonarjee W, Omland T, Nilsen DW, Caidahl K, Sundsfjord JA, et al. Plasma proatrial natriuretic factor (1-98) concentration after myocardial infarction: relation to indices of cardiac and renal function. Br Heart J 1995; 73: 511-6.
6. Kohno M, Yasunari K, Yokokawa K, Murakawa K, Horio T, et al. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest 1991; 87: 1999-2004.
7. McClure SJ, Caruana L, Davie AP, Goldthorp S, McMurray JJ. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998; 317: 516-9.
8. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
9. Clerico A, Iervasi G, Del Chicca MG, Emdin M, Maffei S, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998; 21: 170-9.
10. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. Circulation 1987; 75: 126-33.
11. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK. Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 1997; 29: 641-7.
12. Ebina T, Takahashi N, Mitani I, Sumita S, Ishigami T, et al. Clinical implications of cardiac (123)I-meta-iodobenzylguanidine scintigraphy and cardiac natriuretic peptides in patients with heart disease. Nucl Med Commun 2002; 23: 795-801.
13. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
14. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003; 41: 1264-72.
15. Morgan HE, Gordon EE, Kita Y et al. Biochemical mechanism of cardiac hypertrophy. Ann Rev Physiol 1987; 49: 533-43.
16. Fleck SJ, Pattany PM, Stone MH, Kraemer WJ, Thrush J, et al. Magnetic resonance imaging determination of left ventricular mass: junior Olympic weightlifters. Med Sci Sports Exerc 1993; 25: 522-7.
17. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, et al. The heart in hypertension. N Engl J Med 1992; 327: 998-1008.
18. Komuro I, Kaida T, Shibazaki Y, Kurabayashi M, Katoh Y, et al. Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem 1990; 265: 3595-8.
19. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 101: 2206-12.
20. Weiner HL, Swain JL. Acidic fibroblast growth factor mRNA is expressed by cardiac myocytes in culture and the protein is localized to the extracellular matrix. Proc Natl Acad Sci U S A 1989; 86: 2683-7.
21. Allen SP, Wade SS, Prewitt RL. Myogenic tone attenuates pressure-induced gene expression in isolated small arteries. Hypertension 1997; 30: 203-8. 8
22. Sobue T, Yokota M, Iwase M, Ishihara H. Influence of left ventricular hypertrophy on left ventricular function during dynamic exercise in the presence or absence of coronary artery disease. J Am Coll Cardiol 1995; 25: 91-8.
23. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 1992; 117: 502-10.